Education
About Us
Working with TipRanks
Follow Us
Inoviq Ltd (AU:IIQ)
ASX:IIQ
IIQ Stock Chart & Stats
AU$0.40
AU$0.02(3.09%)
At close: 4:00 PM EST
AU$0.40
AU$0.02(3.09%)
Day’s Range― - ―
52-Week RangeAU$0.32 - AU$0.69
Previous CloseN/A
Volume76.26K
Average Volume (3M)196.06K
Market Cap
AU$45.05M
Enterprise ValueAU$29.83M
Total Cash (Recent Filing)AU$13.80M
Total Debt (Recent Filing)AU$270.31K
Price to Earnings (P/E)―
Beta0.61
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume262,451
30 Day Avg. Volume196,057
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces fixed financing costs and preserves financial flexibility. For a capital-intensive life sciences developer, this gives runway to fund R&D, pursue partnerships, or withstand clinical timelines without immediate refinancing pressure, a durable balance-sheet strength.
Focused Oncology PlatformConcentrated expertise in exosome diagnostics and immuno-oncology targets structurally large oncology markets with high clinical need and barriers to entry. Platform technologies can produce multiple products/services, enabling long-term revenue streams and differentiation if clinical validation succeeds.
Lean Operating StructureA small, focused team supports capital efficiency and lower fixed overhead, extending cash runway during R&D and validation phases. For an early-stage biotech, a lean structure aids nimble development and partnership negotiation, reducing pressure for immediate large-scale commercial resources.
Bears Say
Declining Revenue TrendSustained revenue decline undermines product-market validation and limits reinvestment capacity. For a company dependent on progressing diagnostics and commercialisation, falling sales reduce funding options, slow clinical/commercial milestones, and increase reliance on external financing or partnerships.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate the business is consuming capital to operate and develop products. Over months, this forces dilutive fundraising, licensing compromises, or project delays, threatening the company’s ability to complete clinical programs and commercial rollout without external capital.
Ineffective Equity UtilisationA deeply negative ROE signals the company is not translating invested equity into profits. Persisting low or negative returns erode investor confidence, hamper future capital raises, and indicate structural issues in business model execution or commercialisation pathways that must be resolved for sustainable growth.
Inoviq Ltd News
IIQ FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest share price was AU$0.32 and its highest was AU$0.69 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is AU$45.05M.
When is Inoviq Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inoviq Ltd’s earnings last quarter?
Currently, no data Available
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in AU:IIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.83%
12-Months-Change
Fundamentals
Return on Equity
-37.78%
Trailing 12-Months
Asset Growth
-14.97%
Trailing 12-Months
Company Description
Inoviq Ltd
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---